Here’s why Moderna is sliding (January 8)

Traders Union
All News
Financial News
Moderna Slides 5.66% Today

Highlights

Moderna submitted applications for marketing authorization of its mRNA-1010 seasonal flu vaccine in the U.S., EU, Canada, and Australia after Phase 3 data showed 27% relative efficacy in adults 50 and older.
The company is advancing its pipeline with Phase II and III trials for the mRNA-4157 cancer vaccine in partnership with Merck, as well as additional oncology and rare disease programs.
Moderna is investing $140 million to expand its Massachusetts manufacturing facility and is now facing a patent infringement lawsuit from Bayer's Monsanto over COVID-19 vaccine mRNA technology.

Pipeline progress and legal dispute drive sentiment shift

Moderna submitted applications for marketing authorization of its mRNA-1010 seasonal flu vaccine in the U.S., EU, Canada, and Australia, based on Phase 3 data showing 27% relative efficacy in adults 50 and older. The company is advancing its pipeline, including ongoing Phase II and III trials for its mRNA-4157 cancer vaccine developed with Merck, along with other oncology and rare disease programs. In addition, Moderna is investing $140 million in expanding its Massachusetts manufacturing facility and is now involved in a patent infringement lawsuit brought by Bayer's Monsanto over mRNA technology used in COVID-19 vaccines.

Anton Kharitonov, expert at Traders Union, notes that MRNA's bullish technical structure is increasingly at odds with recent price action. He points out that the sharp daily decline and close near session lows indicate sellers gaining control despite constructive longer-term momentum. The ongoing patent litigation adds a layer of fundamental risk, while modest vaccine efficacy data and volatile trading reinforce a cautious stance. Elevated indicators like RSI and CCI suggest the stock may be overbought and vulnerable to pullbacks if support at $33 fails. "With legal uncertainties and short-term pressures evident, I see downside risk outweighing potential rewards for new entries here," Kharitonov says.

Viktoras Karapetjanc, expert at Traders Union, views Moderna’s pipeline momentum and global market expansion as strengthening the long-term outlook. He finds the bullish technical foundation complemented by continued investments and regulatory progress on multiple vaccine fronts. Despite the recent pullback, he argues the market structure remains robust and offers diverse setups for buyers. Ongoing innovation in oncology and rare diseases presents further upside catalysts. "Moderna’s forward drive and strong trend offer compelling opportunities for further growth in the coming weeks," Karapetjanc says.

Parshwa Turakhiya, analyst, highlights the current volatility and sharp move lower as both risk and opportunity for active traders. He sees overbought readings in key oscillators and a gap down as signals to watch for short-term mean reversion or quick momentum-based setups around supports like $33 and resistances at $35. Turakhiya notes sentiment remains mixed, with intraday pressure countering a still-intact broader uptrend. "Traders should look for clear intraday signals and protect capital, as the current setup could swing quickly in either direction," Turakhiya advises.

Pressure emerges as short-term drop contrasts bullish momentum

The current price of $33.86 remains above the MA-20 ($31.41), MA-50 ($27.67), and MA-200 ($27.41), indicating a prevailing bullish structure on all observed timeframes. With Ichimoku showing the price well above the Kijun at $30.50, this level serves as the closest dynamic support, while the next upside resistance is the round level at $35. Momentum signals are split: the daily MACD remains positive and in buy territory, and ADX points to a strengthening trend, yet several intraday timeframes show opposing signals. RSI (69.41) and CCI (176) indicate overbought conditions, with Stoch RSI neutral but close to overbought as well; BBP signals buyers are dominating, supporting intraday bullishness. Awesome Oscillator is positive, aligning with the broader uptrend. The stock slid 5.66% to $33.86, opening with a small gap down from $35.89 to $35.28, and it now trades near today’s low of $33.73 after elevated intraday volatility. The sharp drop and close near the session low suggest notable pressure after the open, diverging from longer-term momentum, which remains constructive.

Previously it was reported that Moderna Inc displayed a bullish technical structure, trading above key moving averages with momentum indicators such as MACD and ADX indicating continued buyer strength, while volatility remained elevated. Support was identified at the Ichimoku Kijun level and resistance shifted near recent highs as the price consolidated, with technical signals favoring further gains unless a reversal below defined support levels occurs, as detailed in support was identified at the Ichimoku Kijun level.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.